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Genetic Evidence in Yeast Model Implicates Autophagy in the Degradation 
of Parkinson’s Disease Protein α-Synuclein 
 
Kayla Ahlstrand and Peter Sullivan* 
Department of Biology 
Lake Forest College 
Lake Forest, Illinois 60045 
 
Abstract 
 
Parkinson’s disease (PD) is an incurable 
neurodegenerative disease resulting from dopaminergic 
neuronal death in the substantia nigra, likely due to the 
misfolding and aggregation of the protein α-synuclein. A 
major hypothesis is that increasing the degradation of 
α-synuclein reduces toxicity and aggregation. The 
lysosome is pharmacologically implicated in the 
degradation of α-synuclein. Macroautophagy 
(autophagy), a highly conserved catabolic process in 
eukaryotes, is a major route to the lysosome. The 
genetic link between PD and autophagy is currently 
tenuous and a subject of intense research in our lab. In 
this study, we hypothesized that basal autophagy would 
protect cells from α-synuclein toxicity, and tested this 
by genetically inhibiting the nucleation and fusion steps 
of autophagy in a budding yeast model. We assessed α-
synuclein’s pathotoxicity linked properties 
(accumulation, aggregation and toxicity) in yeast 
autophagy gene (ATG) knockout strains needed for 
nucleation (ATG11 and ATG13) and two needed for 
fusion (VAM3 and VAM7).  We are among the first to 
report that autophagy fusion step genes can regulate 
several of α-synuclein’s PD-related properties.  Also, we 
found that the absence of any of these four genes 
altered α-synuclein localization, while three affected its 
accumulation, and none induced cellular toxicity.  These 
new results support accumulating data from our lab for 
the role for autophagy in α-synuclein regulation, but will 
be further aided by completion of analysis of autophagy 
genes yet to be studied. 
 
Introduction 
 
Synucleinopathies lie in the broad realm of 
neurodegenerative disorders and are characterized by the 
aggregation of insoluble α-synuclein protein in various 
regions of the brain (Galvin et al., 2001).  The inclusions 
created by α-synuclein play a major role in the onset of 
Parkinson’s Disease (PD), Lewy body variant of Alzheimer’s 
disease, dementia with Lewy bodies, neurodegeneration 
with brain iron accumulation type-1, and multiple system 
atrophy (Baba et al., 1998; Duda et al., 2000; Galvin et al., 
2009; Spillantini et al., 1997, 1998; Tu et al., 1998). PD is the 
second most common neurodegenerative disease and 
results in resting tremors, bradykinesia, a shuffling gate, and 
postural instability (Olanow and Tatton 1999).  In both 
sporadic and familial PD, dopaminergic neuronal death is 
found in the substantia nigra region of the midbrain, in which 
the misfolded and aggregated α-synuclein accumulates in 
intra-cellular inclusions called Lewy bodies (Spillantini et al., 
1998).  The relationship between α-synuclein and neuronal 
cell death in this devastating disease is still uncertain.   
 α-Synuclein is found abundantly near presynaptic  
terminals of neurons (Clayton and George 1998; Davidson et 
________________________________________________  
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al., 1998; Kahle et al., 2000) and plays a role in regulating 
neurotransmitter vesicle pools (Jensen et al., 1998; Murphy 
et al., 2000), synaptic plasticity (George et al., 1995; 
Abeliovich et al. 2000), phospholipid binding and 
transportation, and lipid metabolism (Davidson et al. 1998; 
Sharon et al., 2001).  The fundamental properties of α-
synuclein leading to PD include misfolding (Winreb et al., 
1996; Uversky 2003), aggregating (Spillantini et al., 1998), 
and binding to cellular membranes (Sharma et al., 2005).  α-
Synuclein shows a gain in toxic function and expresses PD 
symptoms and pathology when over-expressed as wild type 
(WT) or one of its familial mutant forms (A30P or A53T) in 
mice (Masliah et al., 2000; Giasson et al., 2002), flies (Feany 
and Bender 2000; Auluck et al., 2002), and worms (Lasko et 
al., 2003). WT α-synuclein can polymerize in vitro; however, 
mutants A30P (Giasson et al., 1998) and E46K (Greenbaum 
et al., 2005) aggregate more quickly.  The extent of 
aggregation is likely affected by α-synuclein accumulation 
and vice-versa. Thus, the mechanisms that control and, 
most importantly, decrease α-synuclein levels are important 
to understand.  Varying degrees of evidence exist for 
whether the proteasome or the lysosome degrades α-
synuclein and the relative contributions of these two 
pathways need further resolution.   
 Several lines of genetic and chemical evidence 
support α-synuclein degradation via the proteasome.  
Mutations in the Parkin and C-terminal hydroloase-L1 
proteins, both necessary for the proteasome pathway, are 
linked to proteasome dysfunction and PD pathogenesis 
(Schulz 2008; Leroy et al., 1998).  Similarly, chemical 
inhibition of the proteasome results in PD pathogenesis in 
mice models (Petrucelli et al., 2002; McNaught et al., 2004; 
McNaught & Olanow 2006).   Models over-expressing α-
synuclein show that aggregated α-synuclein can lead to 
inhibition of the proteasome, further suggesting the 
relationship between PD and this pathway (Snyder et al., 
2003).  Also, α-synuclein aggregates have an abundance of 
ubiquitin molecules (Ciechanover and Brundin 2003), which 
tag proteins degraded by the proteasome (Hochstrasser 
1996). These relationships indicate that α-synuclein directly 
interacts with the proteasome.    
 More recent evidence increasingly points to the 
lysosome also as a pathway for α-synuclein degradation 
(Lee et al., 2003; Webb et al., 2003; Cuervo et al., 2004; 
Vogiatzi et al., 2008).  Increased accumulation of misfolded 
and aggregated α-synuclein results from the chemical 
inhibition of the lysosome (Lee et al., 2004).  Additionally, 
mice with or without mutations for genes required for normal 
lysosomal function are shown to have increased neuronal 
death, neurodegenerative symptoms, and higher risks for the 
earlier onset of Alzheimer’s Disease, which is pathologically 
similar to PD (Butler et al., 2005).  The lysosome is complex, 
however, in that there are multiple routes to this structure, 
including endocytosis and macroautophagy (autophagy) 
(Luzio et al., 2007; Klionsky).  Evidence exists for α-
synuclein degradation via endocytosis (Willingham et al., 
2003; Alex Ayala, Lake Forest College senior thesis, 2009; 
Jaime Perez, Lake Forest College senior thesis, 2010).  
Autophagy is a cellular mechanism involved in the formation 
of double membrane structures called autophagosomes, 
which fuse with the lysosome to degrade its contents with 
enzymes (Klionsky and Ohsumi 1999). Autophagy is 
comprised of three steps (Figure 1).  Using a mouse model 
for Huntington’s disease, a neurodegenerative disease 
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Figure 1:  Steps of autophagy and associated genes. Shown are the three steps of autophagy accompanied by the genes associated with each 
step.  Genes listed in green have already been assessed by Ray Choi, genes listed in red will be the target of assessment in this paper and genes 
listed in black remain to be assessed in the future.   
 
similar to PD, induction of autophagy protects against 
disease symptoms, while inhibition of autophagy has 
opposite effects (Ravikumar et al., 2004).  Lately, 
Saccharomyces cerevisiae (budding yeast) has become a 
powerful model for exploring α-synuclein pathology (Outeiro 
and Lindquist 2003; Dixon et al., 2005; Flower et al., 2007; 
Sharma et al., 2006; Willingham et al., 2003; Zabrocki et al., 
2005). 
 Recently, the DebBurman lab began evaluating 
autophagy using the budding yeast model.  For his 2009 
thesis, lab colleague Ray Choi analyzed a total of six 
knockout strains, two nucleation genes (ATG17 and VPS15), 
and four expansion genes (ATG1, ATG2, ATG8, and 
ATG18). His results predominately showed alterations in α-
synuclein localization and no changes in toxicity or 
accumulation of α-synuclein (Ray Choi, Lake Forest College 
senior thesis, 2009).  However, several genes still remain to 
be evaluated for nucleation (ATG6, ATG9, ATG11, ATG13, 
ATG14, and VPS34), expansion (ATG3, ATG4, ATG5, and 
ATG10), and all fusion-related genes (VAM3, VAM7, VIT1, 
and YKT6). We aimed to continue and extend Choi’s work 
by evaluating two gene knockouts for nucleation (atg11Δ, 
atg13Δ) and two gene knockouts for fusion (vam3Δ, and 
vam7Δ) in yeast cells.  ATG11 functions in cytoplasmic to 
vacuole targeting (CVT) and brings receptor-bound cargo to 
the phagophore assembly site (PAS) (Yorimitsu and 
Klionsky 2005; Cheong et al., 2008).  ATG13 is used in 
vesicle formation and in the CVT pathway (Funakoshi et al., 
1997; Scott et al., 2000; Reggiori et al., 2004; Kabeya et al., 
2005).   VAM3 is required for vacuolar assembly and 
functions with VAM7 in vacuolar protein trafficking (Wada et 
al., 1992; Srivastava and Jones 1998; Sato et al., 1998).  
VAM7 also functions in the fusion of the lysosome and 
vacuole (Ungermann and Wickner 1998).   
 Specifically, in this study, we tested whether the 
three α-synuclein properties (aggregation, accumulation, and 
toxicity) would change in the four knockout strains assessed.  
We found increased α-synuclein aggregation in atg11Δ and 
vam7Δ, increased accumulation in atg11Δ, and no α-
synuclein-dependent toxicity in yeast cells.  We are also 
among the first to report that fusion related genes affect 
some of α-synuclein’s PD-related properties.  	  
 
Materials and Methods 
 
The following methods are described in detail in Sharma et 
al. (2006) and are briefly summarized below:  
 
α-Synuclein Constructs 
Human wild-type (WT) mutant α-synuclein cDNAs were a gift 
from Christopher Ross (Johns Hopkins University).  A30P 
and E46K were created from WT and α-synuclein and 
confirmed by sequencing (University of Chicago).  WT and 
mutant α-synuclein were subcloned into pYES2.1 vectors 
(Invitrogen) after C-terminus GFP tagging as described in 
Sharma et al (2006).  
 
Yeast Strains 
BY4741, and all autophagy gene deletion strains derived 
from BY4741 parent strain, were purchased from Open 
Biosystems. 
 
Yeast Expression 
Budding yeast α-synuclein expression plasmid vectors 
(pYES2.1) were transformed into budding yeast strains as 
described in Burke et al. (2000).  For selection, yeast cells 
were grown on synthetic-complete media lacking uracil (SC-
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Figure 2: α-Synuclein Properties in BY4741 parent strain. A. Microscopy: Live cell GFP imaging of a-synuclein distribution at 24 and 48 hrs. B. 
Expression: Western blot of a-synuclein and GFP alone expression (anti-V5) at 24 hours inBY4741 lysates.  PGK serves as loading control. C. Serial 
Dilution Spotting: Five-fold serially diluted spotting-cells spotted on to glucose (non-induced) and galactose (induced) plates and grown for two days. D. 
Growth Curve:  OD600 readings over 30-hr for BY4741 cells induced for a-synuclein, GFP, or vector alone. 
 
 
URA).  Presence of α-synuclein constructs was confirmed by 
polymerase-chain reaction.  To regulate the expression of α-
synuclein, the pYES2.1 vector contained a galactose 
inducible promoter (GAL1) allowing α-synuclein expression 
only when grown on in the presence of galactose.  
 
GFP Microscopy 
Yeast cells were grown in 5 mL SC-URA glucose overnight 
at 30°C and 200 rpm. After sufficient growth, cells were 
washed twice in 5 mL H2O by centrifuging at 1500 g for 5 
minutes at 4°C. Cells were resuspended in 10 mL SC-URA 
galactose and incubated at 30°C and 200 rpm. At 24 and 48 
hours, 1 mL of cell culture was centrifuged and 4 µL of cells 
were pipetted onto a slide. Cells were visualized under a 
Nikon TE2000-U fluorescent microscope and images were 
acquired using Metamorph 4.0 imaging software.  
 
Western Analysis 
Yeast cells were grown in glucose, washed, and 
resuspended in 10 mL galactose. At 24 and 48 hours, cell 
lysates were made from 2.5 x 107 cells/mL yeast cells.  Cells 
were washed in 100 mM NaN3 and solubilized in 
Electrophoresis Sample Buffer (ESB) [2% sodium dodecyl 
sulfate (SDS), 80 mM Tris (Ph 6.8), 10% glycerol, 1.5% 
dithiothreitol, 1 mg/mL bromophenol blue, and a cocktail of 
protease inhibitors] and solubilizing agents (1% Triton-X 100, 
1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 
mM sodium orthovanadate, 0.7 µg/mL pepstatin A, 0.5 
µg/mL leupeptin, 10 µg/mL E64, 2µg/mL aprotinin, and 2 
µg/mL chymostatin).   Samples were run on pre-cast 10-20% 
Tris-Glycine gels (Invitrogen) using SDS containing running 
buffer. SeeBlue (Invitrogen) was used as the molecular 
standard. Gels were transferred to PVDF membranes and 
Western blot was performed with anti-V5 (Invitrogen) to 
visualize α-synuclein and anti-phosphoglycerokinase (PGK; 
Molecular Probes) as a loading control.  
 
Spotting Analysis 
Yeast cells were grown in 5 mL SC-URA glucose overnight 
at 30°C (200 rpm), centrifuged at 1500 g for 5 min at 4°C, 
washed twice in 5 mL H2O, and resuspended in 10 mL H2O. 
Cells were counted and diluted to 2.0 x 107 cells/ mL then 
serially diluted (5-fold) into 96-well microwell plates. Pipetting 
was used to spot cells onto SC-URA glucose (2%) and 
galactose (2%) plates. Plates were incubated at 30°C until 
colonies could be seen up to the fifth dilution.  
 
Growth Curve Analysis 
Yeast cells were grown in 5 mL SC-URA glucose overnight 
at 30°C and 200 rpm.  Cells were centrifuged at 1500 g for 5 
min at 4°C, washed twice in 5 mL H2O and resuspended in 
10 mL H2O. Cells were counted and diluted to 2.0 x 106 cell/ 
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Figure 3: α-Synuclein properties in nucleation-compromised strains. A. Microscopy: Live cell GFP imaging of a-synuclein distribution at 24 and 48 
hr in atg11Δ and atg13Δ strains. B. Expression & Accumulation: Western blot of a-synuclein and GFP alone expression (anti-V5) at 24 hours 
comparing BY4741 to atg11D (left) and atg13D (right) lysates.  PGK serves as loading control. C. Serial Dilution Spotting: Cells spotted on to glucose 
(non-induced) and galactose (induced) plates after five-fold serial dilutions for atg11D (left) and atg13D (right) strains. D. Growth Curve: OD600 
readings over 30 hr for to atg11D (left) and atg13D (right) strains. Cells were induced for GFP and WT, A30P, and E46K a-synuclein. 
 
 
mL in 25 mL SC-URA galactose in 125 mL flasks and 
incubated at 30°C and 200 rpm for 48 hrs.  At 0, 3, 6, 12, 18, 
24, 36, and 48 hours from inoculation, duplicate readings of 
1 mL of culture from each flask was placed in a cuvette to 
measure absorbance using a Hitachi U-2000 
Spectrophotometer.  Averaged duplicate readings were used 
to produce a growth curve of absorbance vs. time.   
  
Results  
 
In our budding yeast model of α-synuclein, we analyzed how 
α-synuclein PD-related properties were affected when two 
steps of autophagy were compromised: nucleation and 
fusion. In nucleation, the genes ATG11 and ATG13 were 
deleted, while in fusion, VAM3 and VAM7 were deleted. 
Deletion strains were compared with the isogenic parent 
strain, BY4741. The experiments were set up with two 
controls (vector and GFP). The vector and GFP controls 
ensured that any resulting changes in α-synuclein 
characteristics were not due to the vector or GFP. Three 
GFP-tagged α-synuclein forms were studied: WT α-
synuclein and two familial  mutants (A30P and E46K). Three 
PD-related characteristics were assessed: 
aggregation/localization by live cell GFP microscopy, 
accumulation by Western blotting, and toxicity by optical 
density 600nm growth curves and serially diluted spotting.  
 
BY4741 Parent Strain Localizes to Plasma Membrane 
Without Toxicity 
The results from BY4741 were used as a control to compare 
the effects of α-synuclein observed in the gene deletion 
strains. As with previous data, BY4741 showed plasma 
membrane localization in WT (Sharma et al., 2006) and 
E46K (Michael White, Lake Forest College senior thesis, 
2007; Michael Fiske, Lake Forest College senior thesis, 
2010) and cytoplasmic diffuseness in A30P (Fig. 2A). No 
accumulation of α-synuclein was seen in any of the α-
synuclein expressing cells of BY4741 (Fig. 2B). Finally, we 
looked at toxicity in BY4741 α-synuclein expressing cells. No 
toxicity was seen in any of the α-synuclein expressing cells, 
as each strain grew similar to one another in both the serial 
dilution spotting and the growth curves (Fig. 2C and D). 
These results were used as a control to compare effects of 
α-synuclein observed in the gene deletion strains.  
 
Absence of ATG11 Increases Aggregation and Induces α-
Synuclein-Independent Toxicity 
Next, we assessed the changes in α-synuclein’s three PD-
related properties in atg11Δ cells, the first of two nucleation-
compromised strains we studied. When compared to the 
parent strain, atg11Δ induced a strong change in localization 
in WT and E46K α-synuclein, which, rather than being 
associated with the plasma membrane, was more 
aggregated in the cytoplasm over a 48-hour time course 
(Fig. 3A). Interestingly, this aggregation correlated well with 
 
 
 100	  
 
Table 1: Summary of α-synuclein properties in autophagy gene deletion strains. This table compares each autophagy deletion strain with the 
parent BY4741 strain on increased aggregation (assessed by GFP microscopy), increased accumulation (assessed by western blot analysis) and 
increased toxicity (assessed by growth curves and serial dilution spotting). Changes were scored as none (no change from BY4741), weak (mild 
change from BY4741) or strong (significant change from BY4741).  The genes we assessed are shown in red. 
 
 
increased accumulation for E46K, but WT and A30P α-
synuclein expression was similar to levels in parent cells 
(Fig. 3B). Serial dilution spotting of atg11Δ demonstrated 
strong cellular toxicity compared to the parent cells (compare 
Fig. 3C to Fig. 2C), but this toxicity was not α-synuclein 
dependent, since GFP and vector cells were also toxic even 
without galactose induction. This surprising α-synuclein-
independent toxicity, in the absence of ATG11, was 
confirmed in growth curve assessments (Fig. 3D).  
 
Absence of ATG13 Increases Cytoplasmic Diffusion of WT 
α-Synuclein 
 Our next step was to compromise another nucleation gene, 
ATG13, to understand how other nucleation genes 
contributed to each of α-synuclein’s three PD-related 
properties. When we compromised nucleation with atg13Δ 
cells, we saw striking differences from the other nucleation 
gene, atg11Δ. Compared to BY4741 parent cells, atg13Δ 
showed mild changes in localization and aggregation in WT 
α-synuclein. Instead of synuclein being cytoplasmically 
diffuse, we saw intracellular aggregates form over 48 hours 
(Fig. 3A). A30P and E46K did not show any changes in 
localization or aggregation when compared to BY4741 
(compare Fig. 2A to 3A). Compared to atg11Δ, atg13Δ 
showed strikingly less changes in localization and 
aggregation (Fig. 3A). We found a possible increase in 
accumulation of α-synuclein in E46K, while WT and A30P 
did not appear to have any accumulation (Fig. 3B). The 
control for the Western analysis did not develop, and due to 
time constraints, this experiment has not yet been repeated. 
Serial dilution spotting of atg13Δ did not show α-synuclein 
toxicity in galactose-induced cells compared to non-induced 
cells (Fig 3C). The surprising lack of toxicity seen in atg11Δ 
was also seen in atg13Δ cells. This lack of toxicity was 
confirmed by the assessment of atg13Δ growth curves (Fig. 
3D).  
 
Absence of VAM3 Alters Localization and Increases 
Accumulation  
We then looked into compromising the less-studied fusion 
step of autophagy. The first gene we assessed was VAM3. 
Compared to BY4741, vam3Δ had mild changes in the  
 
localization of α-synuclein in WT and both familial mutants. 
Each showed a mild increase in cytoplasmic diffuseness of 
α-synuclein (compare Fig. 4A to 2A). Similar to atg11Δ, we 
saw an increase in accumulation of α-synuclein in E46K but 
not in WT or A30P (Fig. 4B). We then assessed toxicity with 
serial dilution spotting and saw no α-synuclein toxicity in 
galactose-induced cells compared to non-induced cells (Fig. 
4C). Growth curves of vam3Δ confirmed the lack of α-
synuclein toxicity (Fig. 4D). 
 
Absence of VAM7 Changes Localization of α-Synuclein  
To further understand the fusion step, we assessed a 
second gene, VAM7, in each of α-synuclein’s three PD-
related properties. We compared vam7Δ results to both 
BY4741 and the other compromised fusion cells, vam3Δ. 
When compared to BY4741, vam7Δ showed significant 
changes in localization and aggregation of α-synuclein. WT 
and E46K both had stronger cytoplasmic diffusion of α-
synuclein while A30P had increased aggregation (compare 
Fig. 4A to 2A). These changes in localization and 
aggregation were significantly different from the other 
compromised fusion gene, vam3Δ. There was no 
accumulation of α-synuclein in WT or either familial mutant. 
Again, this differs from vam3Δ, in which a strong 
accumulation of E46K was seen (Fig. 4B). Like each of the 
other knockout strains we assessed, serial dilution spotting 
of vam7Δ showed no toxicity in galactose-induced cells 
compared to non-induced cells (Fig. 4C). The lack of toxicity 
was confirmed by growth curve analysis of vam7Δ (Fig. 4D).  
 
Discussion 
 
Dysfunction in autophagy, a major protein degradation route 
to the lysosome in our cells, may be responsible for 
increased protein accumulation that contributes to the 
pathology of different neurological disorders (Rubinsztein et 
al., 2006).  The misfolding, aggregation, and eventual 
accumulation of α-synuclein are likely causes of 
dopaminergic cell death in PD patients (Lee et al., 2004).  By 
genetically inhibiting the nucleation and fusion steps of 
autophagy, we hypothesized that autophagy protects cells 
 
Deletion 
Strain 
 
 
Increased 
Aggregation 
 
 
Increased   Accumulation 
 
 
Increased 
Toxicity 
 
atg11Δ 
atg13Δ 
atg17Δ 
Vps15Δ 
strong 
weak 
none 
weak 
strong (E46K) 
none 
none 
weak 
non-syn dependent 
none 
none 
non-syn dependent 
 
atg1Δ 
atg2Δ 
atg3Δ 
atg4Δ 
atg8Δ 
atg18Δ 
 
weak 
strong 
weak 
none 
weak 
weak 
none 
strong (E46K) 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
vam3Δ 
vam7Δ 
weak 
strong 
strong (E46K) 
weak 
none 
none 
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against α-synuclein toxicity.  Here we report four notable 
findings: First and foremost, we are among the first to report  
that the autophagy fusion step genes can regulate several of 
α-synuclein’s PD-related properties. Secondly, compromised 
autophagy consistently alters α-synuclein localization 
(sometimes by enhancing aggregation). Thirdly, 
compromised autophagy only modestly increases 
accumulation.  Lastly, inhibiting autophagy leads to a 
surprising lack of toxicity.  These new results support past 
data from our lab on the analysis of several other autophagy 
gene deletions (Ray Choi, Lake Forest College senior thesis, 
2009; see Table 1). Together, they provide accumulating 
evidence that autophagy is a likely route for α-synuclein 
degradation. 
 
Fusion Step in Autophagy Regulates α-Synuclein  
In strong support of our hypothesis, our first notable finding 
was that fusion genes regulate α-synuclein, as vam3Δ and 
vam7Δ affected both α-synuclein localization and 
accumulation. Previously, only nucleation and expansion 
step genes were studied and shown to alter α-synuclein 
cellular localization (Ray Choi, Lake Forest College senior 
thesis, 2009). We do not know of a published report that has 
evaluated fusion genes in regulating α-synuclein in any 
model organism. This finding is important because it shows 
that all steps of autophagy are likely interacting with α-
synuclein, making a strong case that it is a bona fide 
substrate for the auophagy pathway. Fusion step genes (and 
the formation of autophagosomes) have been implicated in 
other human diseases (Todde et al., 2009) suggesting the 
general importance of this step in cellular function.  One of 
the four fusion genes (YKT6 in yeast) serves in lysosome 
trafficking and neuronal function (Hasegawa et al., 2003). 
Therefore, it will be important to extend our analysis to the 
rest of the fusion genes. 
 
Compromised Autophagy Subtly Alters α-Synuclein 
Mislocalization and Aggregation 
Also in strong support of our hypothesis, our second notable 
finding was that α-synuclein localization changes (atg11Δ 
and vam7Δ) and intracellular aggregates form (atg11Δ) in 
cells with compromised autophagy.  Similarly, Ray Choi 
found a variety of localization changes and a strong increase 
in aggregation in atg2Δ (see Table 1).  Other lab colleagues 
studying endocytosis, Alex Ayala and Jaime Perez, found 
altered localization in a majority of the strains they analyzed, 
which makes both autophagy and endocytosis candidates 
for α-synuclein degradation. 
Deleting atg11Δ previously resulted in a severe 
defect in Cvt vesicle formation (Shintanti et al., 2004).  Since 
the Cvt complex is surrounded by the autophagosome, 
which ultimately fuses with the lysosome to degrade 
proteins, it is possible that any deficiency in the Cvt pathway 
could affect the ability to degrade α-synuclein (Baba et al., 
1997).  Another study showed the accumulation of polyQ40 
aggregates, which are found in cells of patients with 
Huntingtion’s disease, in C. elegans muscle cells and the 
subsequent muscle dysfunction by inactivating autophagy 
genes (orthologs of yeast ATG6, ATG7 and ATG18) (Jia et 
al., 2007).          
 
Weak α-Synuclein Accumulation in Deficient Autophagy  
Our third finding of weak α-synuclein accumulation 
supported our hypothesis to a lesser extent than 
mislocalization and aggregation.  Only the E46K strains of 
atg11Δ, atg13 Δ and vam3Δ showed increased 
accumulation, although the results of atg13Δ have not yet 
been repeated due to time constraints. Previous work by 
Ray Choi shows similar results with the six knockout strains 
he assessed. Of these six previously studied strains, only 
vps15Δ and E46K of atg2Δ showed any increase in α-
synuclein accumulation (Table 1). These effects may have 
been milder than expected, because the specific gene 
knockouts may not be crucial to α-synuclein degradation.  
Not all genes are necessary for autophagy to function 
(Suzuki and Ohsumi, 2007). While ATG13, VAM3, and 
VAM7 are required for autophagy (Kabeya et al., 2005; 
Klionsky and Emr, 2000), ATG11 is not. It is, however, 
required for Cvt pathways (Stromhaug et al., 2004). This 
emphasizes that each gene has a different function, some of 
which may not be necessary for degrading α-synuclein, 
resulting in the mild effects that we saw in accumulation.  
However, in relation to Huntingtion’s disease, a previous 
study showed that mice with ATG5 and ATG7 knockouts 
have increased polyubiquitinated protein accumulation in 
neurons and developed neuronal degeneration (Hara et al., 
2006).   
 
Surprising Lack of Toxicity  
We saw a surprising lack of toxicity in all the strains 
assessed. The only toxicity seen was in atg11Δ, yet this 
toxicity was not α-synuclein dependent, as we observed that 
both α-synuclein expressing and non-expressing cells 
showed similar toxicity. This was not in accordance with our 
hypothesis but was similar to the results previously found by 
Ray Choi, which also show α-synuclein dependent toxicity. 
 One explanation for the lack of toxicity is that 
another pathway is compensating for the inhibition of the 
autophagy pathway to the lysosome. Either the proteasome 
(Webb et al., 2003) or the CMA pathway (Kaushik et al., 
2008) can be upregulated with the inhibition of autophagy.  A 
recent study showed that the inhibition of autophagy 
produces an increase in ubiquitinated proteins suggesting 
that the proteasomal pathway is capable of compensating for 
impaired autophagy (Venkatachalam, K. et al., 2008).  These 
compensatory routes may be enough to prevent toxicity from 
being expressed to the extent expected.  
Other factors may compensate for compromised 
autophagy, including the physical traits of yeast and other 
genes.  Yeast adapt to several stressful conditions, such as 
different temperatures, oxidative conditions, and pH levels 
when used to produce beer (Gibson et al., 2007).  This 
survival skill may also be present in autophagy deficient 
yeast cells.  Moreover, it is possible that another gene is 
compensating for the knocked out gene or that multiple 
genes must be knocked out to produce toxicity.   
 In addition, our model has little to moderate levels 
of α-synuclein, which may explain the small amount of 
toxicity.  In the Lindquist lab, however, a moderate to high 
level of α-synuclein produces cellular toxicity (Outeiro & 
Lindquist, 2003).  Thus, we may have to increase α-
synuclein expression levels to see any toxicity is our model.   
 Lastly, previous studies in our lab on oxidative 
stress and on the proteasome have shown clear α-synuclein 
related toxicity in several strains (Sharma et al, 2006; Alex 
Ayala, Lake Forest College senior thesis, 2009; Jaime 
Perez, Lake Forest College senior thesis, 2010).  Thus, we 
cannot completely disregard toxicity related to α-synuclein 
expression.   
 
Future Studies  
 
Our next goal is to assess all remaining nucleation, 
expansion, and fusion genes.  We can also examine the 
induction of autophagy in which we would predict to see the 
opposite results as originally hypothesized for compromising 
autophagy.  It is not until we complete these experiments 
that we can come to a complete conclusion of α-synuclein 
degradation via autophagy. 
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Conclusion 
 
Our research aimed to uncover the possible link between 
autophagy and α-synuclein related PD pathogenesis.  Most 
notably, we are among the first to analyze the fusion genes 
and report that these genes affect α-synuclein properties.  In 
addition, we found a surprising lack of toxicity and subtle 
changes in α-synuclein localization and accumulation.  With 
incomplete analyses and future experiments, however, we 
cannot establish whether or not autophagy plays a role in α-
synuclein degradation. 
Revealing a definite connection between 
autophagy and PD gives hope for PD treatment.  Scientists 
hypothesize that increasing autophagy may decrease protein 
aggregates in Huntingtion’s disease, which is pathologically 
similar to PD (Ravikumar et al., 2004; Sarkar et al., 2007).  If 
similarly applied to PD patients, the potential to ameliorate 
the devastating effects of this disease may drastically 
increase.     
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